Genomic innovation: technologies for personalised medicine. The AHSN network
Genomic innovation: technologies for personalised medicine. The AHSN network
The increasing personalisation of medicine will have aconsiderable impact on the way we deliver healthcare. Inthe future, health and social care will utilise a whole raft ofnew technology to deliver improvements in personalisedmedicine, which administers care based on the needs ofthe individual rather than a ‘one-size-fits-all’ approach.The AHSN Network has made a significant contribution in the developmentand deployment of innovative technologies, medicines and therapies. As partof the AHSN national prioritisation process, AHSNs have outlined a specificinterest in the development of personalised medicine, and in particular ingenomics technologies. Genomics is a key component in the delivery of theaspirations around personalised medicine, as the effectiveness of a drugor therapy on a patient can differ considerably according to their individualgenetic make-up.By using genomics to understand the most effective mode of care for theindividual, we can improve the impact of treatment. Genomics is a stepchange in personalised medicine, but it should be understood that it is notpersonalised medicine per se. It should be viewed as part of an innovativepersonalised medicine toolkit alongside other diagnostics that has nowexpanded to include a wider family of genomics-related and other ‘omicstechnologies, such as proteomics, transcriptomics and pharmacogenomics.Within this new world of personalised medicine and genomics as outlinedin this report, the AHSN Network has a key role to play in developingcommercial partnerships, new technologies and helping to speed upimplementation and adoption into service. AHSNs have the ability to brokerand network between industry, academia and the public sector, to help tounderstand the evidence requirements for implementation and adoption,encourage and promote the relevant engagement of commissioners, supportthe redesign of existing patient pathways, stimulate the development of newpatient pathways and work to develop innovative roles and responsibilitieswithin the health and social care workforce.I hope this timely and informative report will also be of value to the widerhealth and social care system in guiding future developments and action.
Clark, Tristan
712ec18e-613c-45df-a013-c8a22834e14f
1 March 2020
Clark, Tristan
712ec18e-613c-45df-a013-c8a22834e14f
Clark, Tristan
(2020)
Genomic innovation: technologies for personalised medicine. The AHSN network.
Genomic innovation: technologies for personalised medicine. The AHSN network, , Virtual.
73 pp
.
Record type:
Conference or Workshop Item
(Paper)
Abstract
The increasing personalisation of medicine will have aconsiderable impact on the way we deliver healthcare. Inthe future, health and social care will utilise a whole raft ofnew technology to deliver improvements in personalisedmedicine, which administers care based on the needs ofthe individual rather than a ‘one-size-fits-all’ approach.The AHSN Network has made a significant contribution in the developmentand deployment of innovative technologies, medicines and therapies. As partof the AHSN national prioritisation process, AHSNs have outlined a specificinterest in the development of personalised medicine, and in particular ingenomics technologies. Genomics is a key component in the delivery of theaspirations around personalised medicine, as the effectiveness of a drugor therapy on a patient can differ considerably according to their individualgenetic make-up.By using genomics to understand the most effective mode of care for theindividual, we can improve the impact of treatment. Genomics is a stepchange in personalised medicine, but it should be understood that it is notpersonalised medicine per se. It should be viewed as part of an innovativepersonalised medicine toolkit alongside other diagnostics that has nowexpanded to include a wider family of genomics-related and other ‘omicstechnologies, such as proteomics, transcriptomics and pharmacogenomics.Within this new world of personalised medicine and genomics as outlinedin this report, the AHSN Network has a key role to play in developingcommercial partnerships, new technologies and helping to speed upimplementation and adoption into service. AHSNs have the ability to brokerand network between industry, academia and the public sector, to help tounderstand the evidence requirements for implementation and adoption,encourage and promote the relevant engagement of commissioners, supportthe redesign of existing patient pathways, stimulate the development of newpatient pathways and work to develop innovative roles and responsibilitieswithin the health and social care workforce.I hope this timely and informative report will also be of value to the widerhealth and social care system in guiding future developments and action.
Text
FINAL-AHSN-full-report
More information
Published date: 1 March 2020
Venue - Dates:
Genomic innovation: technologies for personalised medicine. The AHSN network, , Virtual, 2020-07-23
Identifiers
Local EPrints ID: 449400
URI: http://eprints.soton.ac.uk/id/eprint/449400
PURE UUID: 585017f9-40c1-4bf4-8900-12ba2f491088
Catalogue record
Date deposited: 27 May 2021 16:30
Last modified: 17 Mar 2024 03:34
Export record
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
